Draeger, Inc. recalled 188 units of the Vapor 3000 anesthetic vaporizer on November 24, 2025. The devices contained impurities in a component not delivered within specification. Healthcare providers and patients must stop using the devices immediately.
A certain component of affected devices was not delivered within specification and contained impurities.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Draeger, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall affects the Draeger Vapor 3000 anesthetic vaporizer, model number M36500. These devices were distributed worldwide, including across 13 U.S. states such as California and New York. The quantity recalled is 188 units.
The recalled anesthetic vaporizer contains a component that does not meet specifications and includes impurities, which may pose health risks to patients. The situation has been classified as a Class I recall, indicating a high risk of serious injury.
There are no reported incidents or injuries associated with the recall at this time. However, the potential risks from impurities could lead to serious health complications.
Stop using the Draeger Vapor 3000 anesthetic vaporizer immediately. Follow the recall instructions provided by the manufacturer and contact Draeger, Inc. or your healthcare provider for further instructions.
For more information, contact Draeger, Inc. directly. Visit their website or call their customer service for assistance.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.